Recent articles regarding the use of JAK-Inhibition in RA have suggested to avoid in patients with increased CV risk. However, RA itself is considered a CV risk factor. Therefore, it seems that all RA patients would potentially be excluded from JAKi therapy. What risk factors should we really be using to determine CV risk?
Thanks, Dr. @Jasvinder Singh! This approach is ver...